ClinicalTrials.gg
CompletedNCT05918588Updated Jun 26, 2023

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

A Phase 1 interventional study of Belumosudil mesylate and Placebo in Immune System Disorder (Healthy Volunteer), sponsored by Kadmon, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-26.

Sponsored by Kadmon, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 9 years 6 months after the study started (first participant enrolled Nov 2013, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.

Read the detailed description

Up to approximately 37 days including safety follow up period of 30 days after participant is treated with the last dose of study drug.

02

Conditions studied

  • Immune System Disorder (Healthy Volunteer)
03

In context

Immune System Diseases

428 studies on the registry are indexed under Immune System Diseases; 87 are open to participants now.

This study's enrollment of 32 is below the median of 66 across 317 interventional studies indexed under Immune System Diseases.

Browse Immune System Diseases studies →

Lead sponsor

Kadmon, a Sanofi Company is the lead sponsor of 14 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

First submitted after Kadmon Corporation, LLC became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants between the ages of 18 and 55 years, inclusive.
  • Female who was not of .
  • Able to provide written prior to the performance of any study specific procedures.
  • (BMI) range of 19-30 kilogram per square meter (kg/m2), inclusive.

Exclusion criteria

Exclusion Criteria:

  • Past or present disease that is judged by the investigator to have the potential to interfere with the study procedures, compromise safety, or affect the PK evaluations.
  • Known sensitivity to Rho-associated coiled-coil containing serine/threonine protein kinases (ROCK2) inhibitor agents or to any of the constituents of the KD025 formulation.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1

    500 mg KD025 or placebo once daily (QD) for 7 days

    Drug: Belumosudil mesylate · Drug: Placebo

  • Experimental
    Cohort 2

    800 mg KD025 or placebo QD for 7 days

    Drug: Belumosudil mesylate · Drug: Placebo

  • Experimental
    Cohort 3

    500 mg KD025 or placebo twice daily (BID) for 7 days

    Drug: Belumosudil mesylate · Drug: Placebo

  • Experimental
    Cohort 4

    1000 mg KD025 or placebo QD for 7 days

    Drug: Belumosudil mesylate · Drug: Placebo

Interventions

  • Pharmaceutical form: capsule; Route of administration: oral

    Also known as: KD025, SAR445761

  • DrugPlacebo

    Pharmaceutical form: capsule; Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events and serious adverse events

    Safety observations and measurements include AEs, safety laboratory tests, vital sign measurements, physical examinations, and ECGs.

    Time frame: Up to approximately 37 days

Secondary outcomes

  1. Cmax of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]

    Cmax is maximum plasma concentration determined directly from the concentration time profile

    Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7

  2. tmax of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]

    tmax is observed time to reach peak plasma concentration

    Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7

  3. AUC0-24 of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]

    AUC0-24 is area under the plasma concentration-time curve from predose (time 0) to 24 hours Postdose

    Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7

  4. AUCinf of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]

    AUCinf is area under the concentration-time curve from predose (time 0) extrapolated to Infinity

    Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7

  5. Cmin of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]

    Cmin is minimum or "trough" plasma concentration after its administration and just prior to the administration of a subsequent dose as determined from the concentration time profile

    Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7

  6. t1/2 of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)]

    t1/2 is terminal elimination half-life

    Time frame: Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7

07

Study locations

1 site
  • Investigational site
    Buffalo, New York 14202, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Mar 2014, 3 months.

Of 25 industry-sponsored phase 1 interventional studies under Immune System Diseases, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's 3 months is below that.

Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 5 and three quarters within 69.

Immune System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jun 26, 2023
StartActual
Nov 21, 2013
Primary completionActual
Mar 6, 2014
CompletionActual
Mar 6, 2014
Last update
Jun 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05918588
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Nov 21, 2013
Primary completion
Mar 6, 2014
Completion
Mar 6, 2014
Last update
Jun 26, 2023

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion